300347.SZHangzhou Tigermed Consulting Co., Ltd
The schedule
- Sun25Oct
Q3 2026 earnings on October 25 will gauge the company's progress in converting its robust backlog into high-margin revenue amidst a challenging macroeconomic environment in China.
- Sun15Nov
Ongoing US legislative scrutiny regarding Chinese biopharmaceutical service providers threatens Hangzhou Tigermed's overseas revenue, which accounts for nearly half of total sales.
- Sun24Jan
- Mon15Feb
Industry-wide data on biopharmaceutical R&D spending will offer leading indicators for CRO demand, particularly as lower Fed Funds Rates potentially ease biotech funding constraints.
- Tue30Mar
The full-year 2026 earnings report on March 30 will define the narrative for the upcoming year, heavily focusing on the success of the company's multi-regional clinical trial (MRCT) strategy.
- Sun25Apr
- Tue15Jun
Potential updates to FDA and EMA guidelines regarding the acceptability of clinical trial data generated solely in China for global drug applications.
- Sun25Jul
- Sun24Oct
Past
- Fri28Aug
Actual outcome: Bull · $52.80 at outcome
The stock closed at $52.80, surpassing the bear floor and trending toward the bull target. The earnings release showed a revenue beat and optimistic guidance, which signaled improved demand and operational efficiency. These developments reinforced investor confidence, driving the price higher despite a slight EPS miss.
Hangzhou Tigermed will report 1H 2026 earnings on August 28, providing crucial visibility into net income margins and overseas clinical trial bookings.